PBX1 and non-small cell lung carcinoma: To further characterize the effect of S1PR3 in the SPHK1/PBX1 axis of NSCLC, H460 cells were transiently transfected with siRNAs targeting S1PR3 or treated with TY-52156 (a potent S1PR3 antagonist).